RU-486 safety profile
Executive Summary
FDA has "received a few letters about RU-486 expressing concerns about potential new safety risks," Commissioner McClellan says during National Press Club address Aug. 8. "We are carefully evaluating all of that information." The abortifacient is marketed by Danco as Mifeprex; the Bush Administration's theme since taking office has been that FDA will keep an eye on the safety of the drug as it would for any other marketed product (1"The Pink Sheet" Sept. 30, 2002, p. 6)...
You may also be interested in...
FDA Ad Policies Will Be One Issue In Commissioner Confirmation Process
FDA's reconsideration of its authority to regulate drug promotions under the First Amendment is one issue FDA Commissioner nominee Mark McClellan is likely to face during Senate confirmation hearings
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.